Differences in survival by histologic type of pancreatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1766-1773

  Fesinmeyer, Megan Dann ^a,b   Austin, Melissa A ^a,b,c   Li, Christopher I ^a,b   De Roos, Anneclaire J ^a,b   Bowen, Deborah J ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; ENDOCRINE TUMOR; FATALITY; FEMALE; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RACE; RISK FACTOR;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREAS, EXOCRINE; PANCREATIC NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 22244434598     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0120     Document Type: Article

References (39)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
3. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003;27:87-93.
4. Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23:251-75.
5. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
6. Bastidas JA, Poen JC, Niederhuber JE. Pancreas. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical oncology. New York: Churchill Livingstone; 2000.
7. Hollingsworth MA. Proteins expressed by pancreatic duct cells and their relatives. Ann N Y Acad Sci 1999;880:38-49.
8. Cotran RS, Kumar K, Collins T. Robbins pathologic basis of disease. Philadelphia: Saunders; 1999.
9. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86.
10. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003;33:3-14.
11. Lichtenstein DR, Carr-Locke DL. Mucin-secreting tumors of the pancreas. Gastrointest Endosc Clin N Am 1995;5:237-58.
12. Mullan MH, Gauger PG, Thompson NW. Endocrine tumours of the pancreas: review and recent advances. ANZ J Surg 2001;71:475-82.
13. Rindi G, Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer 2003;10:427-36.
14. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004;198:722-31.
15. Simunovic M, To T, Theriault M, Langer B. Relation between hospital surgical volume and outcome for pancreatic resection for neoplasm in a publicly funded health care system [see comment]. CMAJ 1999;160: 643-8.
16. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57; discussion 257-60.
17. Surveillance, Epidemiology, and End Results (SEER) Program (http:// www.seer.cancer.gov) Public-Use Data (1973-2000), National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission; 2003.
18. Surveillance, Epidemiology, and End Results (SEER) Program Website. http://www.seer.cancer.gov. 2004, accessed September 24, 2004.
19. Stata version 8.2. College Station (TX): Stata Corporation.
20. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data. Wiley series in probability and statistics. New York: John C. Wiley & Sons; 1999.
21. Sahmoun AE, D'Agostino RA Jr, Bell RA, Schwenke DC. International variation in pancreatic cancer mortality for the period 1955-1998. Eur J Epidemiol 2003;18:801-16.
22. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000;11:915-23.
23. Maire F, Hammel P, Terris B, et al. Prognosis of malignant indraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002;51:717-22.
24. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database [see comment]. J Am Coll Surg 1999;189:1-7.
25. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
26. Brawley OW. Hormonal prevention of prostate cancer. Urol Oncol 2003;21:67-72.
27. Collins J, Crosignani PG, The ESHRE Capri Workshop Group. Hormones and breast cancer. Hum Reprod Update 2004;10:281-93.
28. Skinner HG, Michaud DS, Colditz GA, et al. Parity, reproductive factors, and the risk of pancreatic cancer in women. Cancer Epidemiol Biomarkers Prev 2003;12:433-8.
29. Kreiger N, Lacroix J, Sloan M. Hormonal factors and pancreatic cancer in women. Ann Epidemiol 2001;11:563-7.
30. Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 2005;103:349-57.
31. Longnecker DS, Karagas MR, Tosteson TD, Mott LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, Blacks, and Whites in the United States. Pancreas 2000;21:338-43.
32. Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 2003;14:761-6.
33. DeNavas-Walt C, Proctor BD, Mills RJ. Income, poverty, and health insurance coverage in the United States: 2003. Washington (DC): U.S. Department of Commerce, Economics, and Statistics Administration; 2004.
34. Hall SE, Holman CD, Wisniewski ZS, Semmens J. Prostate cancer: socio-economic, geographical, and private-health insurance effects on care and survival. BJU Int 2005;95:51-8.
35. Kelz RR, Gimotty PA, Polsky D, Norman S, Fraker D, DeMichele A. Morbidity and mortality of colorectal carcinoma surgery differs by insurance status. Cancer 2004;101:2187-94.
36. Okunade AA, Karakus MC. Mortality from breast carcinoma among US women: the role and implications of socio-economics, heterogeneous insurance, screening mammography, and geography. Health Care Manag Sci 2003;6:237-48.
37. Niedergethmann M, Rexin M, Hildenbrand R, et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 2002;26:1578-87.
38. Pernick NL, Sarkar FH, Philip PA, et al. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas 2003;26:28-32.
39. Anton-Culver H, Ziogas A, Bowen DJ, et al. The Cancer Genetics Network: recruitment results and pilot studies. Community Genet 2003;6:171-7.